Answers are grounded in this paper and cite their sources.
Our head-to-head study demonstrated that liraglutide enhanced impaired brain activation and restored impaired cognitive domains in patients with type 2 diabetes, whereas dapagliflozin and acarbose did not. The results expand the clinical application of liraglutide and provide a novel treatment strategy for individuals with diabetes and a high risk of cognitive decline.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: